Rebion’s first commercial product is the blinq.® vision scanner, the first and only device FDA cleared to detect amblyopia and strabismus (lazy eye), is a transformative device that in just seconds measures eye fixation to detect lazy eye, the leading cause of pediatric vision loss and the #1 cause of monocular vision in loss in adults 20 to 70 years of age.
Amblyopia and strabismus are functional impairments in the brain when left untreated before adolescence can lead to permanent vision loss. blinq.® provides a functional test that detects disease with unprecedented success compared to technologies that identify risk factors for disease.
Clinical studies published in August 2021 show 100% sensitivity and 90% specificity for detecting amblyopia, strabismus and other referral warranted disease.
Policy recommended vision screening powered with blinq.® ensure referral warranted cases are not missed while reducing false referrals.
Own a blinq.® for $250/mo.
Ask about our free BabySee App!